7F8H

Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.234 
  • R-Value Observed: 0.239 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Anantharajan, J.Baburajendran, N.Lin, G.Loh, Y.Y.Xu, W.Ahmad, N.H.B.Liu, S.Jansson, A.E.Kuan, J.W.L.Ng, E.Y.Yeo, Y.K.Hung, A.W.Joy, J.Hill, J.Ford, H.L.Zhao, R.Keller, T.H.Kang, C.

(2022) Protein Sci 31: 422-431

  • DOI: https://doi.org/10.1002/pro.4234
  • Primary Citation of Related Structures:  
    7F8G, 7F8H

  • PubMed Abstract: 

    Human eyes absent (EYA) proteins possess Tyr phosphatase activity, which is critical for numerous cancer and metastasis promoting activities, making it an attractive target for cancer therapy. In this work, we demonstrate that the inhibitor-bound form of EYA2 does not favour binding to Mg 2+ , which is indispensable for the Tyr phosphatase activity. We further describe characterization and optimization of this class of allosteric inhibitors. A series of analogues were synthesized to improve potency of the inhibitors and to elucidate structure-activity relationships. Two co-crystal structures confirm the binding modes of this class of inhibitors. Our medicinal chemical, structural, biochemical, and biophysical studies provide insight into the molecular interactions of EYA2 with these allosteric inhibitors. The compounds derived from this study are useful for exploring the function of the Tyr phosphatase activity of EYA2 in normal and cancerous cells and serve as reference compounds for screening or developing allosteric phosphatase inhibitors. Finally, the co-crystal structures reported in this study will aid in structure-based drug discovery against EYA2.


  • Organizational Affiliation

    Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), Singapore.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Eyes absent homolog 2A [auth B],
B [auth A],
C
294Homo sapiensMutation(s): 0 
Gene Names: EYA2EAB1
EC: 3.1.3.48
UniProt & NIH Common Fund Data Resources
Find proteins for O00167 (Homo sapiens)
Explore O00167 
Go to UniProtKB:  O00167
PHAROS:  O00167
GTEx:  ENSG00000064655 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO00167
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.234 
  • R-Value Observed: 0.239 
  • Space Group: I 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 144.281α = 90
b = 50.42β = 101.85
c = 144.281γ = 90
Software Package:
Software NamePurpose
HKL-2000data scaling
PHENIXrefinement
PDB_EXTRACTdata extraction
XDSdata reduction
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Research Foundation (NRF, Singapore)SingaporeOFIRG17may050, NMRC/OFIRG/0051/2017

Revision History  (Full details and data files)

  • Version 1.0: 2021-12-29
    Type: Initial release
  • Version 1.1: 2022-02-23
    Changes: Database references
  • Version 1.2: 2023-11-29
    Changes: Data collection, Refinement description